OCGN Ocugen Inc: Company Cash Funds

Brandmark of Ocugen, Inc. (OCGN)

Geopolitical risks have hindered the international registration of gene therapies from Ocugen, Inc. (OCGN). Changes in the cash balance visualize these challenges, with the value of 0.08 capturing the metric level. In response, Ocugen, Inc. (OCGN) has focused on launching vision restoration technologies in the US, leveraging government contracts and diversifying raw material supplies to eliminate research delays.

OCGN - Ocugen Corp Company Cash and Cash Equivalents over the range 07/04/2022 - 11/21/2026

Analytical breakdowns for Ocugen, Inc.

- stock quotes and analyst forecast:
- company stock capitalization data:
Analysis of all company metrics:ocugen.com
Brand item of Ocugen

This metric tracks the volume of liquid assets on accounts, determining the company's ability to sustain operational activities without external borrowing. A decline in balances signals a high burn rate, while stagnant reserves in the absence of growth indicate management inefficiency. By analyzing cash capital dynamics, an investor assesses the business's financial stability. For Ocugen, Inc. (OCGN), these resources are critically important when implementing strict bioethics standards and ESG security in laboratories.

Competitors of Ocugen, Inc.

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|Company Total Cash Amount MGTX|Company Cash Volume RGNX (regenxbio.com)|SLDB: Company Cash and Cash Equivalents|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume